Tags

Type your tag names separated by a space and hit enter

Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study.
J Clin Psychopharmacol. 2010 Oct; 30(5):531-40.JC

Abstract

The incidence of treatment-emergent extrapyramidal symptoms (EPSs) and tardive dyskinesia (TD) in schizophrenic patients, and the clinical characteristics associated with an increased risk of developing EPSs and TD were examined. Patients (N = 7728) in the 3-year, prospective, observational Schizophrenia Outpatient Health Outcomes study were examined according to baseline antipsychotic drug exposure. At baseline, 4893 patients (63.3%) had no EPS, and 6921 (89.6%) had no TD. Extrapyramidal symptoms and TD were assessed separately during follow-up: frequency and time to appearance from Kaplan-Meier survival curves and factors associated with time to appearance using Cox proportional hazard regression models. The cumulative incidence of EPS ranged from 7.7% (olanzapine) to 32.8% (depot typical drugs). Compared with olanzapine, patients taking depot typical drugs, oral typical drugs, risperidone, and amisulpride had a significantly higher risk of developing EPS. Differences from clozapine were marginally significant. High baseline clinical severity was associated with a significantly higher risk of developing EPS. The incidence of TD ranged from 2.8% (olanzapine) to 11.1% (depot typical agent). Compared with olanzapine, patients taking depot typical agents, oral typical agents, and risperidone had a significantly higher risk of developing TD. Baseline factors associated with a significantly higher risk of developing TD were age, EPS, a higher negative Clinical Global Impression score, and presence of gynecomastia. In summary, patients treated with typical antipsychotic agents (oral and depot) and risperidone had a higher risk of developing EPS and TD than patients treated with olanzapine. Higher baseline clinical severity was associated with EPS development, whereas age, presence of EPS, a higher negative Clinical Global Impression score, and presence of gynecomastia were associated with TD development.

Authors+Show Affiliations

Lilly Research Centre, Eli Lilly and Company, Windlesham, Surrey, United Kingdom. Novick_diego@lilly.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20814320

Citation

Novick, Diego, et al. "Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia: Thirty-six-month Results From the European Schizophrenia Outpatient Health Outcomes Study." Journal of Clinical Psychopharmacology, vol. 30, no. 5, 2010, pp. 531-40.
Novick D, Haro JM, Bertsch J, et al. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531-40.
Novick, D., Haro, J. M., Bertsch, J., & Haddad, P. M. (2010). Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. Journal of Clinical Psychopharmacology, 30(5), 531-40. https://doi.org/10.1097/JCP.0b013e3181f14098
Novick D, et al. Incidence of Extrapyramidal Symptoms and Tardive Dyskinesia in Schizophrenia: Thirty-six-month Results From the European Schizophrenia Outpatient Health Outcomes Study. J Clin Psychopharmacol. 2010;30(5):531-40. PubMed PMID: 20814320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. AU - Novick,Diego, AU - Haro,Josep Maria, AU - Bertsch,Jordan, AU - Haddad,Peter M, PY - 2010/9/4/entrez PY - 2010/9/4/pubmed PY - 2011/8/9/medline SP - 531 EP - 40 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 30 IS - 5 N2 - The incidence of treatment-emergent extrapyramidal symptoms (EPSs) and tardive dyskinesia (TD) in schizophrenic patients, and the clinical characteristics associated with an increased risk of developing EPSs and TD were examined. Patients (N = 7728) in the 3-year, prospective, observational Schizophrenia Outpatient Health Outcomes study were examined according to baseline antipsychotic drug exposure. At baseline, 4893 patients (63.3%) had no EPS, and 6921 (89.6%) had no TD. Extrapyramidal symptoms and TD were assessed separately during follow-up: frequency and time to appearance from Kaplan-Meier survival curves and factors associated with time to appearance using Cox proportional hazard regression models. The cumulative incidence of EPS ranged from 7.7% (olanzapine) to 32.8% (depot typical drugs). Compared with olanzapine, patients taking depot typical drugs, oral typical drugs, risperidone, and amisulpride had a significantly higher risk of developing EPS. Differences from clozapine were marginally significant. High baseline clinical severity was associated with a significantly higher risk of developing EPS. The incidence of TD ranged from 2.8% (olanzapine) to 11.1% (depot typical agent). Compared with olanzapine, patients taking depot typical agents, oral typical agents, and risperidone had a significantly higher risk of developing TD. Baseline factors associated with a significantly higher risk of developing TD were age, EPS, a higher negative Clinical Global Impression score, and presence of gynecomastia. In summary, patients treated with typical antipsychotic agents (oral and depot) and risperidone had a higher risk of developing EPS and TD than patients treated with olanzapine. Higher baseline clinical severity was associated with EPS development, whereas age, presence of EPS, a higher negative Clinical Global Impression score, and presence of gynecomastia were associated with TD development. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/20814320/Incidence_of_extrapyramidal_symptoms_and_tardive_dyskinesia_in_schizophrenia:_thirty_six_month_results_from_the_European_schizophrenia_outpatient_health_outcomes_study_ L2 - https://doi.org/10.1097/JCP.0b013e3181f14098 DB - PRIME DP - Unbound Medicine ER -